BillionToOne told investors it expects its Unity Confirm confirmation test to further differentiate its prenatal genetics suite and increase uptake of its Unity Aneuploidy screening platform. The company said Unity Confirm will be used after high-risk screening results and is designed to avoid invasive follow-up such as chorionic villus sampling (CVS) or amniocentesis. Management said fewer than 1% of screened patients are expected to require follow-up, implying relatively small Unity Confirm volumes. Still, the company expects Unity Confirm to increase screening adoption by making the end-to-end workflow more compelling for providers. BillionToOne is enrolling patients in a prospective trial evaluating Unity Confirm against invasive testing, with enrollment expected to take one to three years. The company also reported an earlier quarterly revenue spike tied to prenatal clinical testing volume growth.